Testing Cerebral Spinal Fluid Circulating Tumor DNA in Adults with Aggressive B-cell Lymphoma at High Risk for Central Nervous System Relapse

What this Trial Is About

Researchers are studying people with aggressive B-cell lymphoma who are at high risk for central nervous system CNS relapse. They want to find out how many of these patients test positive for circulating tumor DNA ctDNA in their cerebral spinal fluid CSF even when standard tests show no CNS involvement. The study also aims to compare how often CNS relapse occurs in patients with and without detected CSF ctDNA. Participants considered at high risk for CNS relapse are identified based on clinical factors such as CNS-IPI score, specific genetic changes like MYC, BCL2, and BCL6 translocations, and involvement of certain extranodal sites including breast, renal, adrenal, nasopharyngeal, and epiduralparaspinal areas. The study uses a CSF ctDNA test developed by Memorial Sloan Kettering Cancer Centers Diagnostic Molecular Pathology core, which is approved by the New York State Department of Health. All participants will undergo this diagnostic testing while receiving standard frontline therapy for their lymphoma. During the study, participants will be monitored to see if the CSF ctDNA test is positive and followed for up to two years to observe the incidence of CNS relapse. Researchers will collect data on CSF ctDNA presence and track clinical outcomes related to CNS relapse. Participants must be able to undergo lumbar puncture safely for CSF collection and will be assessed regularly during their standard treatment. The total participation time will vary depending on individual treatment and follow-up schedules.

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma